Radioiodine Therapy of Hyperthyroidism

Chapter

Abstract

Thyroid benign disorders have been successfully treated by means of administration of 131iodine since the 1940s. The efficacy and safety of this treatment and the advantages over thyroid surgery made its success worldwide. In this chapter we outline indication, Patients preparation and precautions regarding radioiodine. We also discuss the procedures and the safety and side effects of this treatment.

Keywords

Hyperthyroidism Goitre Radiometabolic treatment Graves Basedow Toxic nodules Graves’ ophtalmopathy Thyrotoxicosis 

References

  1. 1.
    Chapman EM. History of the discovery and early use of radioactive iodine. JAMA. 1983;250(15):2042–4.CrossRefPubMedGoogle Scholar
  2. 2.
    Stokkel MPM, Handkiewicz DJ, Lassmann M, et al. EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. 2010;37:2218–28.CrossRefPubMedGoogle Scholar
  3. 3.
    Silberstein EB, Abass A, Balon HR, et al. The SNM practice guideline for therapy of thyroid disease with 131I 3.0. JNM. 2012;53(10):1633–51.CrossRefPubMedGoogle Scholar
  4. 4.
    Rivkees SA. Controversies in the management of Graves’ disease in children. J Endocrinol Investig. 2016;39:1247–57.CrossRefGoogle Scholar
  5. 5.
    Cooper DS. Hyperthyroidism. Lancet. 2003;362:459–68.CrossRefPubMedGoogle Scholar
  6. 6.
    Franklyn JA. The management of hyperthyroidism. N Engl J Med. 1994;330:1731–8.CrossRefPubMedGoogle Scholar
  7. 7.
    McDermott MT, Woodmansee WW, Haugen BR, et al. The management of subclinical hyperthyroidism by thyroid specialists. Thyroid. 2003;13:1133–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Biondi B, Bartalena L, Cooper DS, et al. The 2015 European Thyroid Association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. Eur Thyroid J. 2015;4:149–63.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Carle A, Andersen SL, Boelaert K, et al. Management of endocrine disease: subclinical thyrotoxicosis: prevalence, causes and choice of therapy. Eur J Endocrinol. 2017;176(6):R325–37.  https://doi.org/10.1530/EJE-16-0276.CrossRefPubMedGoogle Scholar
  10. 10.
    Wesche MF, Tiel-V Buul MM, Lips P, et al. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter. J Clin Endocrinol Metab. 2001;86:998–1005.CrossRefPubMedGoogle Scholar
  11. 11.
    Braga M, Walpert N, Burch HB, et al. The effect of methimazole on cure rates after radioiodine treatment for Graves’ hyperthyroidism: a randomized clinical trial. Thyroid. 2002;12:135–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Santos RB, Romaldini JH, Ward LS. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves’ disease. Thyroid. 2004;14:525–30.CrossRefPubMedGoogle Scholar
  13. 13.
    West JD, Cheetham TD, Dane C, et al. Should radioiodine be the first-line treatment for paediatric Graves’ disease? – review article. J Pediatr Endocrinol Metab. 2015;28(7-8):797–804.CrossRefPubMedGoogle Scholar
  14. 14.
    Bal CS, Kumar A, Pandey RM. A randomized controlled trial to evaluate the adjuvant effect of lithium on radioiodine treatment of hyperthyroidism. Thyroid. 2002;12:399–405.CrossRefPubMedGoogle Scholar
  15. 15.
    Lazarus JH. Guidelines for the use of radioiodine in the management of hyperthyroidism: a summary. The Radioiodine Audit Subcommittee of the Royal College of Physicians Committee on Diabetes and Endocrinology, and the Research Unit of the Royal College of Physicians. J R Coll Physicians Lond. 1995;29:464–9.PubMedGoogle Scholar
  16. 16.
    Collier A, Gosh S, Hair M, et al. Comparison of two fixed activities of radioiodine therapy (370 vs. 555 MBq) in patients with Graves’ disease. Hormones (Athens). 2009;8:273–8.CrossRefGoogle Scholar
  17. 17.
    Hagen GA, Ouellette RP, Chapman EM. Comparison of high and low dosage levels of 131-I in the treatment of thyrotoxicosis. N Engl J Med. 1967;277(11):559–62.CrossRefPubMedGoogle Scholar
  18. 18.
    Bachmann J, Kobe C, Bor S, et al. Radioiodine therapy for thyroid volume reduction of large goitres. Nucl Med Commun. 2009;30:466–71.CrossRefPubMedGoogle Scholar
  19. 19.
    Rivkees SA, Sklar C, Freemark M. Clinical review 99: the management of Graves’ disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab. 1998;83:3767–76.PubMedGoogle Scholar
  20. 20.
    Ma C, Kuang A, Xie J, et al. Radioiodine treatment for pediatric Graves’ disease. Cochrane Database Syst Rev. 2008;3:CD006294.Google Scholar
  21. 21.
    Rivkees SA, Cornelius EA. Influence of iodine-131 dose on the outcome of hyperthyroidism in children. Pediatrics. 2003;111(4 Pt 1):745–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158:273–85.CrossRefPubMedGoogle Scholar
  23. 23.
    Hall P, Berg G, Bjelkengren G, et al. Cancer mortality after iodine-131 therapy for hyperthyroidism. Int J Cancer. 1992;50:886–90.CrossRefPubMedGoogle Scholar
  24. 24.
    Hall P, Boice JD, Berg G, et al. Leukaemia incidence after iodine-131 exposure. Lancet. 1992;340:1–4.PubMedGoogle Scholar
  25. 25.
    Dobyns BM, Sheline GE, Workman JB, et al. Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study. J Clin Endocrinol Metab. 1974;38:976–98.CrossRefPubMedGoogle Scholar
  26. 26.
    Read CH, Tansey MJ, Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves’ patients. J Clin Endocrinol Metab. 2004;89:4229–33.CrossRefPubMedGoogle Scholar
  27. 27.
    Royal College of Physicians. Radioiodine in the management of benign thyroid disease: clinical guidelines. Report of a Working Party. London: RCP; 2007.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Nuclear Medicine UnitHumanitas Research HospitalRozzanoItaly

Personalised recommendations